An FDA-approved tesamorelin product exists: EGRIFTA, by Theratechnologies, application 022505, a Purple Book biologic. What that approval covers, why an Orange Book search misses it, and why none of it attaches to a research vial.
A plain review of every indexed Cartalax (AED) paper: what was measured, in which cells, by whom, and the three studies where AED was the null result.
Every published human study of NAD+ itself, reported precisely: a 180-patient heart-failure trial and an 11-person infusion pilot with a negative finding.
Two published human studies tested NAD+ itself. About 45 randomized trials tested NR or NMN precursors. Why the two evidence bases must never be merged.
No published human interventional trial of MOTS-c exists. The registry record stated precisely, the biomarker-versus-intervention distinction, and the counter-evidence set.
Zero human studies exist for 5-Amino-1MQ or any NNMT inhibitor. How that zero was verified across seven PubMed searches and a registry query, and what it means.
GHK-Cu has exactly two human randomized trials, published in 1992 and 2006. Both were topical, and both were negative on every objective endpoint measured.
Semax has four PubMed records carrying a clinical-trial tag. None were run outside Russia, and the only randomized one reported a negative primary endpoint.
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).